Political Shift Offers Boost to Redcare Pharmacy Shares

Redcare Pharmacy shares surge over 20% as proposed higher prescription co-payments could drive patients to online pharmacies, forcing short sellers to cover positions.

After a prolonged period of decline, shares of Redcare Pharmacy have found an unexpected source of support from political developments. Proposals from a government-appointed expert commission for substantial reforms to the statutory health insurance system could structurally benefit the business model of online pharmacies. The mere prospect of these changes was sufficient to lift the company's stock from a recent multi-year low.

Short Sellers Forced to Cover

This shift in fundamental outlook intersected with a market characterized by a significant level of short interest. Upon the announcement of the commission's plans, market observers noted that short sellers began buying shares to close their positions. This covering activity added further momentum to the upward price movement.

Despite a weekly surge of over 20%, the shares closed at €37.22 on Thursday evening. For the year to date, the stock remains down by approximately 44%. The company continues to face fundamental pressure from the entry of drugstore chains such as dm and Rossmann into the over-the-counter (OTC) medication market. In response to this competition, Redcare recently revised its growth expectations for this segment downward, from 16% to a range of 8-10%.

Co-Payments as a Potential Catalyst

The core driver behind the sudden optimism is a proposed increase in prescription medication co-payments. Currently, patients pay between €5 and €10 per prescription. The finance commission has suggested raising these fees by 50%, which would shift the range to €7.50 to €15.

Metzler Bank analyst Felix Dennl identifies this as a clear potential advantage for mail-order pharmacies. Higher out-of-pocket costs are likely to incentivize price-sensitive consumers to switch from local brick-and-mortar pharmacies to more affordable online providers. Federal Health Minister Nina Warken has already announced her intention to initiate corresponding legislative procedures promptly.

Operational Milestones Ahead

Regardless of the ongoing political debate in Berlin, the company's management faces several key operational dates in the coming weeks:

• April 15, 2026: Annual General Meeting, featuring the formal election of the new CFO, Hendrik Krampe.
• May 6, 2026: Publication of financial results for the first quarter of 2026.

These upcoming quarterly figures will serve as the first true performance test for the new leadership team. Market focus will be particularly sharp on the robust prescription medication (Rx) segment, where Redcare is targeting revenue exceeding €670 million for 2026 to counterbalance the persistent weakness in OTC sales.